Fubotv earnings beat by $0.10, revenue topped estimates
Verastem, Inc. (NASDAQ:VSTM) President and CEO Dan Paterson sold 1,332 shares of common stock on August 6, 2025, at a price of $5.81, totaling $7,738. The biotech company’s stock has shown remarkable strength, delivering a 157% return over the past year. According to InvestingPro analysis, the stock appears slightly undervalued at current levels. The transaction is related to covering statutory withholding requirements tied to the vesting of restricted stock units. Following the transaction, Paterson directly owns 442,507 shares of Verastem. With the company’s market capitalization at $314 million and analysts maintaining a strong buy consensus, investors should note that Verastem will report earnings on August 8, 2025. For deeper insights and additional analysis, check out the comprehensive research report available on InvestingPro.
In other recent news, Verastem Oncology has received Fast Track Designation from the U.S. Food and Drug Administration for its oral KRAS G12D inhibitor, VS-7375, aimed at treating pancreatic cancer with KRAS G12D mutations. This designation applies to the first-line treatment of locally advanced or metastatic pancreatic adenocarcinoma and for patients who have undergone at least one prior line of standard therapy. Additionally, Verastem has published promising data from its Phase 2 RAMP 201 clinical trial in the Journal of Clinical Oncology, showing a 31% overall response rate for its combination therapy of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer. The response rate was higher at 44% in patients with KRAS mutations. Updated results from the Phase 1/2 FRAME study also revealed a 42.3% overall response rate and 20.1 months median progression-free survival in LGSOC patients, with even stronger outcomes in those with KRAS mutations. Furthermore, Verastem has initiated a Phase 1/2a clinical trial for VS-7375 in patients with advanced KRAS G12D mutant solid tumors. This trial, which will expand globally, begins with a monotherapy dose-escalation phase and will include expansion cohorts in pancreatic cancer and non-small cell lung cancer patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.